Prognostic and Immunological Role of Adaptor Related Protein Complex 3 Subunit Mu2 in Colon Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jan 4

PMID 38177168

Authors

Qianqian Jin

Jiahao Feng

Yang Yan

Yong Kuang

Affiliations

Soon will be listed here.

Abstract

The expression levels and prognostic role of AP3M2 in colorectal adenocarcinoma (CRAC) have yet to be fully unveiled. Our study comprehensively investigated the clinical significance of AP3M2 in colorectal cancer through an extensive bioinformatics data mining process (TCGA, GEO, GEPIA, Timer, Ualcan, ROCPLOT, and David), followed by experimental validation. We found AP3M2 is a cancer gene, which can be used to distinguish between colorectal cancer and colorectal adenomas, liver metastasis, lung metastasis, colorectal polyp. Higher AP3M2 expression levels were associated with longer overall survival in colon adenocarcinoma. AP3M2 might be the primary biomarker for oxaliplatin in colon cancer and an acquired resistance biomarker for oxaliplatin and 5-fu. AP3M2 was positively associated with CD274, CTLA4. AP3M2 might be associated with T-cell, NF-kappaB transcription factor activity, and response to hypoxia. AP3M2 could predict chemotherapy effectiveness and prognosis for colon cancer patients. AP3M2 might inhibit tumor growth via influencing tumor-infiltrating immune cells in the context of Tumor microenvironment. AP3M2 plays as an oncogene in CRAC and is suggested as a new potential biotarget for therapy.

References

Schmiegel W, Pox C, Arnold D, Porschen R, Rodel C, Reinacher-Schick A . Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int. 2010; 106(51-52):843-8. PMC: 2803611. DOI: 10.3238/arztebl.2009.0843. View

Lewis C, Murdoch C . Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005; 167(3):627-35. PMC: 1698733. DOI: 10.1016/S0002-9440(10)62038-X. View

Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T . Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 2007; 446(7136):685-9. DOI: 10.1038/nature05673. View

Lewis B, Shih I, Jones-Rhoades M, Bartel D, Burge C . Prediction of mammalian microRNA targets. Cell. 2003; 115(7):787-98. DOI: 10.1016/s0092-8674(03)01018-3. View

Wang M, Windgassen D, Papoutsakis E . Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics. 2008; 9:225. PMC: 2396644. DOI: 10.1186/1471-2164-9-225. View

Gao Y, Sun Z, Gu J, Li Z, Xu X, Xue C . Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer. Front Oncol. 2021; 11:748465. PMC: 8640083. DOI: 10.3389/fonc.2021.748465. View

Huang M, Okada M, Nakatsu F, Oguni H, Ito M, Morita K . Mutation screening of AP3M2 in Japanese epilepsy patients. Brain Dev. 2007; 29(8):462-7. DOI: 10.1016/j.braindev.2006.12.004. View

Abdullah L, Chow E . Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013; 2(1):3. PMC: 3565873. DOI: 10.1186/2001-1326-2-3. View

Enwere E, Kornaga E, Dean M, Koulis T, Phan T, Kalantarian M . Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017; 30(4):577-586. DOI: 10.1038/modpathol.2016.221. View

10.

Rappaport N, Twik M, Plaschkes I, Nudel R, Iny Stein T, Levitt J . MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 2016; 45(D1):D877-D887. PMC: 5210521. DOI: 10.1093/nar/gkw1012. View

11.

Cui M, Zhang H, Han S, Huo F, Shen Z, Ding D . Screening of biomarkers associated with diagnosis and prognosis of colorectal cancer. Genes Genet Syst. 2022; 97(3):101-110. DOI: 10.1266/ggs.21-00072. View

12.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

13.

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

14.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

15.

Nakatsu F, Okada M, Mori F, Kumazawa N, Iwasa H, Zhu G . Defective function of GABA-containing synaptic vesicles in mice lacking the AP-3B clathrin adaptor. J Cell Biol. 2004; 167(2):293-302. PMC: 2172536. DOI: 10.1083/jcb.200405032. View

16.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

19.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

20.

Iliopoulos D, Hirsch H, Struhl K . An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009; 139(4):693-706. PMC: 2783826. DOI: 10.1016/j.cell.2009.10.014. View